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Background: The P2X7 receptor plays an important role in cytokine release during the inflammatory response
in vivo. Polymorphisms within the P2X7 receptor gene that lead to loss of receptor function may contribute to
impaired cytokine release by immune cells. Therefore, we investigated whether a known loss-of-function
polymorphism (Glu496Ala) in the P2X7 receptor gene leads to alterations in cytokine release in response to ATP.
Results: An ex vivo whole blood model was used to induce an inflammatory reaction with the pro-inflammatory
stimuli LPS and PHA (phytohemagglutinin). Blood from n=9 subjects with the Glu496Ala P2X7 SNP (P2X7MUT) and
n=7 ‘wild-type’ subjects (no P2X7 SNP; P2X7WT) was used.
Addition of ATP (0.9-3 mM) to LPS/PHA-stimulated whole blood induced an increase in IL-1β release in P2X7MUT
subjects, whereas decreased release was observed in P2X7WT subjects. Decreased levels of IL-6 and TNF-α in
response to ATP were shown in both P2X7MUT and P2X7WT subjects, which was less pronounced in P2X7MUT
subjects. ATP at 3 mM also significantly decreased levels of lactate dehydrogenase (LDH) in P2X7MUT subjects
compared to P2X7WT subjects.
Conclusions: The presence of the non-synonymous Glu496Ala loss-of-function polymorphism within the P2X7
receptor gene is likely to be of importance in the release of cytokines during inflammation. Furthermore, this study
suggests that carriers of the Glu496Ala loss-of-function polymorphism are protected against the cytotoxic effects of
high ATP-levels.
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The innate immune system constitutes the first line
of defense against anything that compromises tissue
homeostasis. Activation of innate immunity results in
the induction of inflammation, which is essence, aims
to restore the structural and functional integrity of
tissues and organs.
Adenosine 50-triphosphate (ATP) is thought to be one
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reproduction in any medium, provided the orand cytokine storm. It is present in high concentrations
within the cytoplasm of every cell and can be released
after cell damage by a variety of injurious agents [1,2].
After release, ATP acts through binding to specific
receptors known as purinergic P2 receptors (P2R), of
which the P2X7 subtype is a potent mediator of cytokine
processing and release [3].
The purinergic P2X7 receptor is a ligand-gated ion
channel which has a wide tissue distribution, being
expressed by virtually all cell types, including cells of the
immune system, i.e. monocytes, macrophages, dendritic
cells, and T cells [4]. Activation of this receptor by brief
exposure to extracellular ATP opens a cation channel,
which allows Ca2+ influx, as well as K+ efflux [5]. Longer
exposure to ATP leads to dilatation of the P2X7 channelral Ltd. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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size of ethidium+ [6,7]. Activated P2X7 receptors are
known to play an important role in regulating the in-
flammatory response in vivo (reviewed in [8]. Research
indicates that activation of the P2X7 receptor causes
massive release of the pro-inflammatory mediator IL-1β.
The P2X7-mediated release of IL-1β by immune cells is
suggested to be regulated by various mechanisms includ-
ing: a) cytotoxicity of IL-1β producing immune cells [9],
b) K+ efflux [9], and c) activation of the inflammasome
NALP3 via pannexin-1 (reviewed in [10]). In addition to
IL-1β, other pro-inflammatory mediators are also up-
regulated via P2X7 receptor, including IL-6, IL-18 and
TNF-α (reviewed in [11]).
These data point to an important role of P2X7
receptor-mediated signaling in inflammation, and also
suggest that polymorphisms within the P2X7 receptor
gene that lead to loss of receptor function have the po-
tential to impair cytokine release by immune cells
in vivo.
Several non-synonymous single nucleotide poly-
morphisms (SNP) have been characterized in the P2X7
receptor gene (reviewed in [12]). One such SNP con-
cerns the nucleotide at position 1513, which changes a
glutamic acid to an alanine acid at amino position 496
(Glu496Ala). Previous research in human monocytes,
showed that the Glu496Ala polymorphism decreased
the P2X7 receptor mediated K
+ efflux, thereby delaying
P2X7 receptor mediated release of IL-1β [13]. Further-
more, it was shown that subjects homozygous for the
variant allele of the Glu496Ala polymorphism had
reduced sensitivity to inflammation compared to wild-
type subjects [14]. In the present study, we further
tested the hypothesis that subjects homozygous for
the Glu496Ala loss-of-function polymorphism produce
lower levels of IL-1β in response to ATP. In addition
to levels of IL-1β, we also explored whether produc-
tion of other inflammatory cytokines in response to
ATP was altered in subjects carrying the Glu496Ala
P2X7 receptor SNP.Table 2 Effect of LPS + PHA stimulation on the release of cytok




IL-1β 2.2 ± 0.16 2.6 ± 0.35 0.381
TNF-α 6.6 ± 1.04 7.1 ± 0.33 0.694
IL-6 2.5 ± 0.21 2.5 ± 0.35 0.965
IL-10 2.4 ± 0.21 2.0 ± 0.10 0.190
IFN-γ 15.4 ± 3.93 13.4 ± 6.38 0.792
a)Data are shown as mean ± SEM.To test our hypotheses, we used an ex vivo inflam-
mation model by stimulating whole blood with the
potent inflammatory stimuli LPS and PHA (phytohem-
agglutinin). Previous research showed that this whole
blood assay, in contrast to isolated cells or cell lines
grown in medium, closely resembles the in vivo situ-
ation and forms an appropriate and reproducible
culture condition to measure cytokine production
ex vivo [15].Results
Study population
Of the eligible 14 P2X7MUT subjects, a total of 9
P2X7MUT (aged 50-75 years; 2 men and 7 women)
donated blood for this ex vivo experiment. Two out
of these 9 P2X7MUT subjects showed no other SNPs
in the P2X7 receptor gene. The other seven subjects
were shown to have several other non-synonymous
SNPs in the P2X7 receptor gene in addition to the
Glu496AlaP2X7 receptor polymorphism (Table 1).
Of the eligible 19 P2X7WT subjects, a total of 7
P2X7WT (aged 55-74 years; 1 man and 6 women) were
willing to donate blood.Effects of LPS/PHA stimulation on cytokine release
Stimulation of whole blood from P2X7MUT subjects
with LPS + PHA for 24 hours induced a strong rise in
levels of IL-1β, TNF-α, IL-6, IL-10 and IFN-γ (Table 2).
No statistically significant differences in IL-1β, TNF-α,
IL-6, IL-10 and IFN-γ levels in unstimulated whole
blood in the absence of ATP were observed between
P2X7MUT and P2X7WT subjects. In LPS/PHA-stimu-
lated blood, levels of IL-1β and TNF-α tended to be
slightly higher and levels of IL-6, IL-10 and IFN-γ
tended to be slightly lower in LPS/PHA-stimulated
whole blood from P2X7MUT subjects, even though the
differences were not statistically significant (Table 2).
No effect of the P2X7 receptor on the production of
the other measured cytokines (i.e. IL-2, IL-7, IL-8, IL-12,ines (Release of IL-1β, TNF-α, IL-6, IL-10 and IFN-γ in
s homozygous for the Glu496Ala polymorphism
Stimulated p-value
P2X7WT P2X7MUT
5,644 ± 3,261 3,440 ± 1,647 0.529
7,784 ± 3,470 5,173 ± 1,380 0.504
13,922 ± 5,790 19,804 ± 8,003 0.064
291 ± 104 305 ± 167 0.968












Figure 1 Cytokine and LDH release A-E LPS/PHA-induced cytokine release in response to 24 h stimulation by ATP at different
concentrations (0.3, 0.9 and 3 mM), in subjects without the Glu496Ala P2X7 receptor polymorphism (P2X7WT) vs. subjects with this
SNP (P2X7MUT). Results are expressed as percent change from baseline (LPS/PHA-stimulation without ATP incubation) ± SEM. E LDH release in
response to ATP stimulation in subjects without the Glu496Ala P2X7 receptor polymorphism (P2X7WT) vs. subjects with this SNP (P2X7MUT)
* Significant difference between P2X7MUT and P2X7WT (p < 0.05).
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observed (data not shown).
Effect of the Glu496Ala polymorphism on IL-1β release in
response to ATP
The effect of ATP at different concentrations on LPS/
PHA–induced IL-1β release in whole blood after
24hours is shown in Figure 1A. ATP at a concentration
of 0.3mMhad no effect on the LPS/PHA-induced IL-1β
release among P2X7WT subjects, whereas IL-1β levels in
blood from P2X7MUT subjects were increased to 160%
of levels at 0 mM ATP. At higher ATP concentration IL-
1β levels in blood from P2X7WT subjects were reduced
(i.e. 57% and 4.7% of baseline levels at 0.9mM and 3mM
ATP respectively), whereas P2X7MUT subjects showed
increased levels of IL-1β (i.e. 151% and 173% of baseline
levels at 0.9mM and 3mM ATP respectively) Thedecreased IL-1β levels observed at the ATP concentra-
tion of 0.9mM was consistent in 6 out of the 7 P2X7WT
subjects, and the almost complete abolishment of IL-1β
production in response to 3.0mM ATP was consistent in
all 7 P2X7WT subjects.
When comparing P2X7WT with P2X7MUT subjects,
the IL-1β response of P2X7WT subjects, to ATP at 0.9
and 3 mM was only 65% (p=0.031) and 3% (p=0.058), re-
spectively, of the IL-1β response to ATP observed in
P2X7MUT subjects.
Effects of the Glu496Ala polymorphism on TNF-α,IL-6,
IL-10 and IFN-γ release in response to ATP
Effects of 24-hour LPS/PHA stimulation of whole blood
in the presence of ATP at different concentrations on the
release of TNF-α, IL-6, IL-10 and IFN-γ are shown in
Figure 1B-E. Figure 1B shows that in both P2X7WT and
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cubation with ATP. This effect was consistent in all
studied subjects. Comparing P2X7WT with P2X7MUT
subjects, we observed a significantly stronger reduction
in TNF-α levels relative to baseline in P2X7WT sub-
jects (P2X7MUT vs. P2X7WT: 36% vs. 64% (p=0.008),
60% vs. 83% (0.041), and 67% vs. 99% (p=0.011) at 0.3
mM, 0.9 mM and 3 mM ATP, respectively).
Figure 1C shows that ATP at a concentration of
0.3mMhad no effect on the LPS/PHA-induced IL-6 re-
lease among P2X7WT subjects, whereas a slight in-
crease in IL-6 release to 114% of levels with 0 mM
ATP was observed in P2X7MUT subjects. Both
P2X7WT and P2X7MUT subjects showed a decline in
IL-6 release at 0.9 mM and 3.0 mM ATP compared to
baseline. This inhibition of IL-6 release, however, was
less pronounced in P2X7MUT subjects (P2X7WT:42%
and 100%; P2X7MUT14% and 46%, respectively). The
difference in IL-6 release between P2X7WT and
P2X7MUT subjects was significant at 3 mM (p=0.050).
P2X7WT subjects showed no alteration in the IL-10
release in response to 0.3 mM ATP compared to base-
line levels, and increased levels of IL-10 were observed
at an ATP concentration of 0.9 mM (129%). Again, at
3 mM ATP, the release of IL-10 in blood from
P2X7WT subjects was almost completely abolished, i.e.
a 99% reduction in IL-10 levels compared to baseline
levels. In P2X7MUT subjects, 0.3 mM ATP induced an
increase in LPS/PHA-induced IL-10 release to 122% of
baseline levels (Figure 1D), whereas at ATP concentra-
tions of 3 mM the release of IL-10 in P2X7MUT sub-
jects declined to 45% of baseline levels. These levels
were significantly higher than IL-10 levels in blood
from P2X7WT subjects at 3 mM ATP.
At an ATP concentration of 0.3mM, a 34% reduction
of IFN-γ production compared to baseline was
observed in P2X7WT subjects (Figure 1E). A further
reduction in IFN-γ production was found at 0.9 and 3
mM ATP; 58% and 94%, respectively. In P2X7MUT
subjects also reduced IFN-γ levels were observed at all
ATP concentrations compared to baseline (27%, 39%
and 60%, respectively).ATP measurement in whole blood
No difference in ATP levels were observed between
P2X7MUT and P2X7WT subjects.LDH release
At an ATP concentration of 0.9mM, the release of
LDH showed a slight increase compared to baseline
in P2X7WT and P2X7MUT subjects, to 103% and 112%
of levels without ATP, respectively (Figure 1F). P2X7WT
subjects showed a further increase in the release of LDHat ATP concentration of 3 mM to 135% of the condition
without ATP, whereas a decrease in the release of LDH
to 95% of the condition without ATP was observed in
P2X7MUT subjects. The difference between the change
in P2X7MUT and P2X7WT subjects at 3mM ATP was
statistically significant (p=0.014).
Discussion
In vitro evidence suggests that the P2X7 receptor is
involved in the induction of inflammation. In the present
study, we tested the hypothesis that P2X7MUT subjects
have impaired cytokine release compared to P2X7WT
subjects, using an ex vivo inflammation model. In this
model, blood was stimulated with the potent inflamma-
tory stimuli LPS and PHA to trigger an inflammatory re-
sponse via both the innate and adaptive arms of
immunity, respectively, leading to the production of a
range of different cytokines. Our group previously
showed that stimulatory effects of low-level ATP (i.e.
0.3 mM) on the production of IL-10 were maximal after
24 hours of incubation, and that early inhibitory effects
of 0.3 mM ATP on IL-1β, TNF-α, IL-6 and IFN-γ per-
sisted up to this time point [16]. In the present study,
whole blood from subjects with and without the
Glu496Ala polymorphism in the P2X7 receptor gene
were incubated with ATP concentrations ranging from
0.3 to 3 mM to evaluate effects of this loss-of-function
polymorphism on cytokine release via P2X7.
Contrary to our hypothesis, LPS/PHA-induced IL-1β
release showed a concentration-dependent stimulation
by ATP incubation of blood from P2X7MUT subjects,
whereas ATP induced a concentration-dependent at-
tenuation of the LPS/PHA-induced IL-1β release in
P2X7WT subjects. However, the most striking result
observed in the present study was that release of IL-1β
as well as release of TNF-α, IL-6, IL-10 and IFN-γ was
almost completely abolished in whole blood from
P2X7WT subjects after 24-hour LPS/PHA stimulation in
the presence of 3 mM ATP, whereas such an effect was
not observed in P2X7MUT subjects.
It is known that apoptosis, which is a morphologically
distinct form of cell death [17], is induced in immune
cells by prolonged or excessive activation of the P2X7 re-
ceptor by high levels of ATP [18]. Since impaired P2X7
receptor function in leucocytes from subjects with the
Glu496Ala polymorphism could lead to resistance to
P2X7-mediated apoptosis, we measured LDH levels as
an indicator of ATP-induced cell death in the present
study. Results showed increased LDH levels after 24-
hour exposure to high concentrations of ATP in
P2X7WT subjects, but not in P2X7MUT subjects. This
finding, combined with the striking observation that
levels of all cytokines were almost completely abolished
inP2X7WT subjects after 24-hour LPS/PHA stimulation
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suggest that leucocytes from P2X7MUT subjects were
protected against ATP-induced cell death, presumably
via impaired P2X7-mediated apoptosis. This result is in
line with a previous study, which showed a marked re-
duction in non-viable lymphocytes in P2X7MUT subjects
[7], strengthening the hypothesis that the Glu496Ala
polymorphism indeed causes resistance to apoptosis.
In studies in isolated cell lines, it has been well estab-
lished that extra cellular ATP at high concentrations
triggers massive release of IL-1β, thereby inducing a
strong pro-inflammatory response [19,20]. Numerous
in vitro studies as well as in vivo studies with P2X7 re-
ceptor knock-out mice have demonstrated that the P2X7
receptor is the main receptor responsible for the release
of IL-1β induced by ATP [21-23]. Therefore, polymorph-
isms is the P2X7 receptor gene causing a function
change in the P2X7 receptor, such as the Glu496Ala
polymorphism, could lead to impaired IL-1β releases.
Sluyter et al. [13] previously showed that in whole blood
from subjects harbouring the Glu496Ala polymorphism
IL-1β release was 78% lower than in whole blood from
wild-type subjects after 30 min of 6 mM ATP treatment.
However, after 60 min ATP treatment this inhibition of
IL-1β release was no longer apparent [13]. More re-
cently, also a 6-hour incubation with 1mM ATP did not
induce an attenuation of IL-1β release in P2X7MUT sub-
jects [14]. It has been demonstrated that the Glu496Ala
polymorphism results in impaired ATP-induced pore
formation, but does not cause a total loss of P2X7 chan-
nel function [7]. Indeed, Sluyter et al [24] found that
P2X7MUT subjects showed a reduced but not totally
abolished P2X7 receptor-mediated K
+ efflux compared
to P2X7WT subjects. The authors suggested that the
smaller residual K+ efflux may still be sufficient to cause
delayed release of IL-1β in subjects harbouring the
Glu496Ala polymorphism, offering a putative explan-
ation why no reduction in IL-1β release has been
observed after prolonged incubation with ATP in
monocytes from these subjects. In our study, we
observed even increased levels of IL-1β in P2X7MUT
subjects compared to P2X7WT subjects after 24-hour
ATP incubation. This result might be explained by the
fact that the Glu496Ala SNP incompletely impairs P2X7
receptor function, that is, delaying but not abolishing
the K+ efflux that is essential for IL-1β release, while
impairing pore formation is essential for apoptosis. An-
other possible explanation for the observed increased
IL-1β release in P2X7MUT subjects might be the activa-
tion of immune cells by other proinflammatory cyto-
kines, such as TNF-α and IFN-γ[25,26]. It is difficult,
however, to draw conclusions about differences between
P2X7WT vs. P2X7MUT subjects regarding effects of
ATP at 3 mM on production of IL-1β as well asproduction of other cytokines, since the effects of ATP
at these concentrations in our study appeared to be dis-
torted by cytotoxic effects via P2X7 in P2X7 WT
subjects.
Previous findings showed the involvement of the P2X7
receptor in the ATP-induced secretion of IL-6 in several
diseases [27]. In the present study, however, decreased
levels of IL-6 were observed after incubation of LPS/
PHA stimulated blood with ATP. Furthermore, this de-
crease was less pronounced in P2X7MUT subjects com-
pared to P2X7WT subjects. Future research on the
effects of ATP induced release of IL-6, and the involve-
ment of the P2X7 receptor in IL-6 release is therefore
warranted.
In a previous study by our group in which we used the
whole blood assay to test the influence of ATP on the
release of a number of cytokines [16], it was shown that
co-incubation of whole blood from healthy volunteers
with LPS/PHA and 0.3 mM ATP attenuated the rise of
the pro-inflammatory cytokine TNF-α and stimulated
the secretion of the anti-inflammatory cytokine IL-10.
We demonstrated pharmacologically [28] that the stimu-
lation of TNF-α release and the inhibition of IL-10 re-
lease were due to ATP-induced activation of the
P2Y11and P2Y12 receptor subtypes, respectively. In
agreement with these earlier studies, we found in the
present study that ATP at 0.3 mM decreased TNF-α
levels in both P2X7WT and P2X7MUT subjects. Al-
though pharmacological evidence in rat microglia sug-
gests that TNF-α levels may be increased via activation
of the P2X7 receptor [29], our data would rather suggest
that the P2X7 receptor is not involved in the regulation
of TNF-α release in whole blood ex vivo at low levels of
ATP.
Little is known about the direct regulation of produc-
tion of IL-10 by the P2X7 receptor. Denlinger et al. [14]
showed that P2X7MUT subjects released higher levels
of IL-10 in response to ATP than P2X7WT subjects.
Our data, however, do not show a differential effect of
ATP at 0.3 and 0.9mM on IL-10 in P2X7MUT vs.
P2X7WT subjects.
It is known that hemolysis can significantly increase
plasma ATP concentration [30]. Therefore, the differ-
ences between P2X7MUT and P2X7 WT subjects found
in the present study could have been confounded by the
different amount of hemolysis in the samples of these
subjects. However, our HPLC data shows that the
plasma ATP levels of P2X7MUT and P2X7 WT were
similar and are unlikely to have influenced our results.
In this study we only focused on the role of the P2X7
receptor subtype in the inflammatory response. Several
other members of the P2 purinergic receptor family have
been shown to play a in the ATP induced inflammatory
response [31]. Moreover, recent evidence has indicated a
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P2X7-mediated inflammatory functions [32]. Therefore,
our results might have been influenced by the presence
of non-synonymous SNPs within other P2X receptor
genes causing functional changes of these receptors. In
the body, an interplay exists between bone homeostasis
and immune processes. Research dealing with crosstalk
between the bone and immune system, i.e. the field of
osteoimmunology, is receiving growing attention [33,34].
Bone marrow is the principal site of haematopoiesis
allowing a close interaction between bone and immune
cells. Cytokines released during immune responses are
known to affect the bone metabolism, and dysregulated
cytokine responses are implicated in bone disease such
as osteoporosis. IL-1β as well as TNF-α and IL-6 are
known to promote osteoclastogenesis either by increas-
ing osteoclast generation and activation or by inducing
RANKL expression by osteoblasts [35,36], whereas IL-10
and IFN-γ are known to be inhibitors of osteoclastogen-
esis by blocking RANKL signalling, either directly or in-
directly [35]. Alterations in cytokine release due to the
Glu496Ala polymorphisms leading to loss of P2X7 re-
ceptor function might therefore contribute to the devel-
opment of osteoporosis. As we observed increased levels
of both IL-1β and TNF-α in P2X7MUT subjects relative
to P2X7WT subjects, it might be suggested that
P2X7MUT subjects have an increased risk to develop
osteoporosis. This hypothesis is consistent with previous
reports showing that the Glu496Ala polymorphism,
leading to a non-functional P2X7 receptor, is associated
with decreased BMD values, i.e. increased osteoporosis
risk [37-39].
Conclusions
In conclusion, a difference in the ATP-induced cytokine
release and cell-death was observed between P2X7MUT
subjects and P2X7WT subjects, indicating that the
Glu496Ala loss-of-function polymorphism is likely to
play an important during inflammation. Therefore, the
P2X7 receptor might be of importance in the aetiology
and pathophysiology of inflammatory diseases as well as
related conditions, such as osteoporosis. However, fur-
ther research to unravel the exact role of non-
synonymous SNPs within the P2X7 receptor gene is
warranted.
Methods
Study population and design
For our ex vivo experiment, we recruited participants
from a previously established cohort in which P2X7 re-
ceptor SNPs have been genotyped. This cohort consisted
of 376 men and women aged ≥ 50 years with a recent
fracture. Subjects selected for the present study were
previously identified either as wild type for theGlu496Ala polymorphism, or homozygous for the
Glu496Ala polymorphism. Of the 376 subjects, 14 were
homozygous for the Glu496Ala polymorphism(P2X7MUT),
and 19 were wild-type for the Glu496Ala polymorphism
(P2X7WT) and at the same time for all other genotyped
P2X7 receptor SNPs [37].
All 33 selected subjects were contacted to give exten-
sive oral information about the present study. After
obtaining written informed consent, heparinized blood
was obtained. Blood from fasting subjects was collected
in two 9-ml heparin tubes between 8:30 and 9:30 AM on
the morning of the whole blood experiment.
The study was approved by the ethical committee of
the University Hospital Maastricht and Maastricht
University.
Blood-based cytokine production assay
The whole blood assay was performed according to the
procedures described by Swennen and co-workers
[16,40]. Briefly, concentrations of 17 cytokines (i.e. ma-
ture IL-1β, IL-2, IL-4, IL-5, IL-6, IL-7, IL-8, IL-10, IL-12,
IL-13, IL-17, G-CSF, GM-CSF, IFN-γ, MCP-1, MIP1-β,
TNF-α) were determined in heparinized blood samples,
either unstimulated or stimulated with 10 μg/ml LPS
(lipopolysaccharide) and 1 μg/ml PHA (phytohemagglu-
tinin) to induce an inflammatory reaction, and incubated
with different concentrations of ATP (0, 0.3, 0.9, and 3
mM) for 24 hours, by using Luminex Multiplex X-map
technology (Bio-Rad Laboratories B.V., Veenendaal, the
Netherlands).
Measurement of ATP by luminescence
Samples from the whole blood assay were collected at
different time points following incubation (t=0, 30min
and 2, 4, 6, 24 h) for measurement of ATP levels by
luminescence. Samples were diluted with 50μl Fire Zyme
Dilution Buffer (Bio-Medica Diagnostics, Inc., Windsor,
NS, Canada) and immediately centrifuged at 3000g for
5 min at 4°C. A Cell Titer-Glow ATP-assay kit (Promega
Benelux BV, The Hague, The Netherlands) was used
according to the manufacturer’s instructions to measure
the bioluminescence on a Glomax plate reader.
Lactate dehydrogenase measurement
To measure cytotoxicity, lactate dehydrogenase (LDH)
leakage was estimated. Although this necrotic cell death
marker does not directly measure ATP-induced cell
apoptosis, it is considered a useful marker of apoptosis,
since apoptosis is a transient process leading to second-
ary necrosis [41].
For this, 50 μl cell-free supernatant samples from
the whole blood assay were transferred into 96-well
plates and LDH was measured using the CytoTox96
nonradioactive cytotoxicity assay kit (Promega Benelux
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ATP concentrations of 0.9 and 3mM is expressed as
percentage difference relative to LDH release in LPS/
PHA stimulated samples without ATP incubation.
Since the half maximal concentration of the P2X7 re-
ceptor is approximately 0.5mM, concentrations of
0.3mM ATP were not measured.
Statistical analysis
Results are reported as mean and standard error of the
mean (SEM). Differences in cytokine release between
P2X7MUT and P2X7WT subjects were compared using
independent samples T-tests, after testing for normality
of the distribution. P-values equal to 0.05 or below, were
regarded as statistically significant. All analyses were
performed using SAS, version 9.1.
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